Reports Q1 revenue $103.7M, consensus $102.04. “We’re continuing to build on the momentum we established in fiscal 2025, starting the new fiscal year with our twelfth consecutive quarter of growth. Revenue of $103.7 million exceeded guidance and increased 17% compared to the first quarter of 2025,” said Emily Leproust, CEO and co-founder of Twist Bioscience (TWST). “As we continue through the year and beyond, we remain focused on driving toward profitability with consistent revenue growth, gross margins above 50% and disciplined spending to invest in scalable, sustainable growth opportunities while serving more customers, launching more products and expanding our addressable markets.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Is TWST a Buy, Before Earnings?
- Cathie Wood Doubles Down on Crypto Stocks, Trims Kratos Defense and TWST. Here’s Why
- Cathie Wood Invests Over $3M Into Crypto Stock, Trims Stakes in Kratos Defense and TWST
- Cathie Wood Sells Biotech Stocks, Bets Big on Tempus AI and WeRide
- Twist Bioscience price target raised to $50 from $42 at Guggenheim